SpyGlass Pharma, Inc. 8-K

What Happened

• SpyGlass Pharma, Inc. filed an 8‑K reporting the appointment of Habib Dable to its board of directors on February 5, 2026 and the filing/adoption of an amended and restated certificate of incorporation and bylaws effective February 9, 2026 in connection with the completion of its IPO. The company also issued a press release on February 9, 2026 announcing the closing of its IPO.

Key Details

• Director appointment: Habib Dable appointed as a Class I (non‑employee) director on Feb 5, 2026; will serve on the compensation committee. No arrangements with other persons relating to his election; no Item 404 related‑party transactions disclosed.
• Director compensation: Under the company’s outside director policy, base retainer $40,000/year; additional committee and chair fees range from $5,000 to $30,000/year (details in Registration Statement). Dable received an indemnification agreement in the company’s standard form.
• Equity grant: On Feb 5, 2026 Dable was granted an option to purchase 27,400 shares; vests 1/36th monthly. He will receive annual option grants of 13,700 shares on the first trading day after each annual meeting, subject to continued service.
• IPO closing: Press release states the IPO closed on Feb 9, 2026 for 10,781,250 shares, including 1,406,250 shares issued upon full exercise of the underwriters’ option to purchase additional shares.

Why It Matters

• The filing documents board composition and governance changes tied to the company’s transition to a public company after its IPO. Investors should note the addition of an experienced industry executive (Dable), the director compensation and equity award terms, and the formal adoption of the company’s public‑company charter and bylaws—items that affect governance, dilution, and disclosure going forward. The IPO share count confirms the size of the offering and the underwriters’ exercise of their option.